REVB (Revelation Biosciences) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Revelation Biosciences's cash to debt ratio for the quarter that ended in Dec. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Revelation Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Revelation Biosciences's Cash-to-Debt or its related term are showing as below:

REVB' s Cash-to-Debt Range Over the Past 10 Years
Min: 75 Med: No Debt Max: No Debt
Current: No Debt

During the past 5 years, Revelation Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 75.00. And the median was No Debt.

REVB's Cash-to-Debt is ranked better than
99.87% of 1488 companies
in the Biotechnology industry
Industry Median: 7.4 vs REVB: No Debt

Revelation Biosciences Cash-to-Debt Historical Data

The historical data trend for Revelation Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Revelation Biosciences Cash-to-Debt Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

No Debt

75.00

No Debt

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial											No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Revelation Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Revelation Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Cash-to-Debt falls into.

Revelation Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Revelation Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Revelation Biosciences had no debt ⁽¹⁾.

Revelation Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Revelation Biosciences had no debt ⁽¹⁾.

Revelation Biosciences (NAS:REVB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Revelation Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (NAS:REVB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Executives

George F Tidmarsh	director, 10 percent owner
Lakhmir S Chawla	director	1960 KIRBY ROAD, MCLEAN VA 22101
Axa Im Prime Impact Gp S.a.r.l	other: Former 10% owner	2-4, RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Im Prime Impact Master Fund I Sca Sicav-raif	other: Former 10% Owner	2-4 RUE EUGENE RUPPERT, LUXEMBOURG N4 L-2453
Axa Investment Managers S.a.	other: Former 10% owner	6 PLACE DE LA PYRAMIDE, TOUR MAJUNGA, PUTEAUX I0 92800
Axa Investment Managers Paris	other: Former 10% owner	6 PLACE DE LA PYRAMIDE, PUTEAUX I0 92800
Axa Investment Managers Uk Ltd	other: Former 10% owner	22 BISHOPGATE, LONDON X0 EC2M 3XJ
S.a. Axa	other: Former 10% owner	25 AVENUE MATIGNON, PARIS I0 75008
Jess Roper	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
James Rolke	director, officer: Chief Executive Officer	10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Curt H Labelle	director	C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Jennifer Carver	director	725 NEWPORT STREET, DENVER CO 80220
Zygmont Chester Stanley Iii	officer: Chief Financial Officer	3322 MILLIKIN AVE, SAN DIEGO CA 92122
Lawrence Feis	10 percent owner	190 EAST WALTON PLACE, UNIT 603, CHICAGO IL 60611
Feis Equities Llc	10 percent owner	20 NORTH WACKER DRIVE, SUITE 2115, CHICAGO IL 60606